Bocidelpar
Sponsors
Astellas Pharma Inc, Astellas Pharma Global Development, Inc.
Conditions
Duchenne Muscular Dystrophy (DMD)Healthy VolunteersHepatic ImpairmentPrimary Mitochondrial MyopathyReduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen ExtractionRenal Impairment
Phase 1
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
TerminatedNCT04184882
Start: 2021-02-24End: 2022-09-04Updated: 2024-10-22
A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
TerminatedNCT04855201
Start: 2021-06-14End: 2022-12-16Updated: 2025-04-16
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
CompletedNCT04942964
Start: 2021-09-13End: 2022-01-20Updated: 2024-10-21
A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People
CompletedNCT05117294
Start: 2021-12-21End: 2022-11-22Updated: 2024-10-21